| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324157 | NOVO | Preparation comprising insulin, nicotinamide and an amino acid |
Jun, 2030
(6 years from now) | |
Fiasp is owned by Novo.
Fiasp contains Insulin Aspart.
Fiasp has a total of 1 drug patent out of which 0 drug patents have expired.
Fiasp was authorised for market use on 29 September, 2017.
Fiasp is available in solution;intravenous, subcutaneous dosage forms.
The generics of Fiasp are possible to be released after 25 June, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 19, 2022 |
| New Product(NP) | Sep 29, 2020 |
| M(M-247) | Oct 21, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
More Information on Dosage
FIASP family patents
